Synergistic therapeutic benefit by combining the antibody drug conjugate, depatux-m with temozolomide in pre-clinical models of glioblastoma with overexpression of EGFR-论文-万方医学网

Synergistic therapeutic benefit by combining the antibody drug conjugate, depatux-m with temozolomide in pre-clinical models of glioblastoma with overexpression of EGFR

导出原文传递

翻译打印收藏纠错

作者： Vaidya, Kedar S. ^[1] ; Mitten, Michael J. ^[2] ; Zelaya-Lazo, Adelyn L. ^[3] ; Oleksijew, Anatol ; Alvey, Cory ; Falls, Hugh D. ; Mishra, Sasmita ; Palma, Joann ; Ansell, Peter ; Phillips, Andrew C. ; Reilly, Edward B. ; Anderson, Mark ; Boghaert, Erwin R.

作者单位： AbbVie, Vivo Pharmacol, Global Pharmaceut Res & Dev, 1 N Waukegan Rd, N Chicago, IL 60064 USA ^[1] AbbVie, Oncol Discovery, Global Pharmaceut Res & Dev, 1 N Waukegan Rd, N Chicago, IL 60064 USA ^[2] AbbVie, Translat Oncol, Global Pharmaceut Res & Dev, 1 N Waukegan Rd, N Chicago, IL 60064 USA ^[3]

关键词 Depatux-m Combination therapy EGFR Glioblastoma Temozolomide

发布时间 2021-05-19

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除